- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer scraps once-a-day experimental obesity pill over liver safety concerns
New York: Pfizer Inc said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice daily treatment danuglipron, as it races to rival the success of other weight loss treatments.
The company's shares fell more than 5% in early trading on Monday as Pfizer said it would stop developing its therapy lotiglipron after patients who took the drug in clinical studies were shown to have elevated levels of liver enzymes.
Pfizer CEO Albert Bourla has said an obesity pill could eventually be a $10-billion-a-year product for Pfizer. The company's shares have dropped around 29% so far this year as it works to develop its strategy past the COVID vaccines and therapeutics that drove revenue and earnings for the past few years. The NYSE Arca Pharmaceutical index, which tracks drugmakers, is down around 1% over the same period.
The company said it expects to finalize plans for the danuglipron late-stage program by the end of the year, and is also developing a once-daily, modified release version of that drug. Pfizer has been developing both pills in parallel, but had said all things being equal its preference would be for the once daily lotiglipron.
The news comes days after competitor Eli Lilly released promising data for its own once-daily experimental pill, orforglipron.
Truist Securities analyst Robyn Karnauskas said Lilly is now ahead in the race for a once-a-day obesity pill.
"We believe while (twice a day) has advantages, we really need a (once daily) formulation for weight loss," she said in a research note.
Pfizer said last month that danuglipron helped patients lose weight on par with Novo Nordisk's Ozempic in a mid-stage study that tested it in patients with Type 2 diabetes.
U.S. demand for Wegovy and Ozempic, the brand names for Novo Nordisk's once-weekly injections for treating obesity and diabetes respectively, has soared recently.
The enormous demand for treatments like Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts have said.
None of the patients in the lotiglipron trials reported liver-related symptoms or side effects, there was no evidence of liver failure and none required treatment, Pfizer said.
Liver enzyme elevations observed in lotiglipron trials have not been seen in patients enrolled in danuglipron trials, the company added.
Read also: CDSCO Panel Approves Pfizer's Protocol Amendment Proposal for Marstacimab
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751